

# Swaminathan Padmanabhan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3183770/publications.pdf>

Version: 2024-02-01

159  
papers

7,452  
citations

66343

42  
h-index

58581

82  
g-index

167  
all docs

167  
docs citations

167  
times ranked

9694  
citing authors

#	ARTICLE	IF	CITATIONS
1	Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy. <i>Journal of Clinical Oncology</i> , 2012, 30, 631-636.	1.6	571
2	Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 1749-1755.	1.6	541
3	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. <i>Lancet</i> , The, 2019, 393, 229-240.	13.7	517
4	Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II Study. <i>Journal of Clinical Oncology</i> , 2006, 24, 5343-5349.	1.6	400
5	Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia. <i>Clinical Cancer Research</i> , 2016, 22, 868-876.	7.0	262
6	Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. <i>Blood</i> , 2010, 115, 3796-3800.	1.4	236
7	Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. <i>Leukemia</i> , 2014, 28, 2155-2164.	7.2	232
8	A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. <i>Blood</i> , 2012, 120, 4324-4333.	1.4	217
9	WTAP is a novel oncogenic protein in acute myeloid leukemia. <i>Leukemia</i> , 2014, 28, 1171-1174.	7.2	208
10	Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 1142-1154.	4.1	169
11	Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. <i>Blood</i> , 2011, 118, 5126-5129.	1.4	152
12	Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 1422-1428.	1.6	150
13	Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20 <sup>+</sup> Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3467-3474.	1.6	149
14	Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia. <i>American Journal of Hematology</i> , 2010, 85, 670-674.	4.1	138
15	Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 2871-2883.	5.2	134
16	A Phase I multicentre dose-dense determination study of BHQ880 in combination with anti-multiple myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events. <i>British Journal of Haematology</i> , 2014, 167, 366-375.	2.5	130
17	BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2315-2327.	4.1	123
18	Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. <i>Blood</i> , 2011, 117, 6450-6458.	1.4	121

#	ARTICLE	IF	CITATIONS
19	Allogeneic Vaccination With a B7.1 HLA-A Gene-Modified Adenocarcinoma Cell Line in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 2800-2807.	1.6	103
20	Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma. <i>Blood</i> , 2021, 137, 3272-3276.	1.4	95
21	Oligonucleotide aptamer-drug conjugates for targeted therapy of acute myeloid leukemia. <i>Biomaterials</i> , 2015, 67, 42-51.	11.4	91
22	Pre-clinical efficacy of combined therapy with novel $\beta$ -catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells. <i>Leukemia</i> , 2015, 29, 1267-1278.	7.2	84
23	Parsaclisib, a potent and highly selective PI3K $\gamma$ inhibitor, in patients with relapsed or refractory B-cell malignancies. <i>Blood</i> , 2019, 133, 1742-1752.	1.4	84
24	Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. <i>Cancer</i> , 2011, 117, 2127-2135.	4.1	77
25	Ganciclovir Inhibits Lymphocyte Proliferation by Impairing DNA Synthesis. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 765-770.	2.0	74
26	Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 897-908.	2.3	73
27	High prevalence of early-onset osteopenia/osteoporosis after allogeneic stem cell transplantation and improvement after bisphosphonate therapy. <i>Bone Marrow Transplantation</i> , 2008, 41, 393-398.	2.4	71
28	The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib. <i>Journal of Cellular and Molecular Medicine</i> , 2011, 15, 2057-2070.	3.6	70
29	Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 3943-3951.	5.2	69
30	Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors. <i>Targeted Oncology</i> , 2009, 4, 99-105.	3.6	68
31	Phase I study of MLN8237, investigational Aurora A kinase inhibitor, in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia. <i>Investigational New Drugs</i> , 2014, 32, 489-499.	2.6	67
32	Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. <i>Blood</i> , 2019, 133, 2765-2775.	1.4	63
33	CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. <i>Blood Advances</i> , 2021, 5, 2799-2806.	5.2	57
34	Romidepsin for the Treatment of Peripheral T-Cell Lymphoma. <i>Oncologist</i> , 2015, 20, 1084-1091.	3.7	55
35	Characteristics and Treatment of Advanced Breast Implant-Associated Anaplastic Large Cell Lymphoma. <i>Plastic and Reconstructive Surgery</i> , 2019, 143, 41S-50S.	1.4	55
36	Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. <i>American Journal of Hematology</i> , 2020, 95, 623-629.	4.1	54

#	ARTICLE	IF	CITATIONS
37	Phase 1/1<sc>B</sc> trial of the heat shock protein 90 inhibitor <sc>NVP</sc>â€<sc>AIY</sc>922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma. Cancer, 2015, 121, 2185-2192.	4.1	51
38	Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXOâ€dependent mechanism. International Journal of Cancer, 2012, 131, 2693-2703.	5.1	50
39	Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic Tâ€cell lymphoma. Hematological Oncology, 2017, 35, 914-917.	1.7	50
40	An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis. Blood, 2022, 139, 1098-1110.	1.4	46
41	A unique aptamer-drug conjugate for targeted therapy of multiple myeloma. Leukemia, 2016, 30, 987-991.	7.2	45
42	SMARCAD1 Phosphorylation and Ubiquitination Are Required for Resection during DNA Double-Strand Break Repair. IScience, 2018, 2, 123-135.	4.1	44
43	Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K Î³/Î³ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma. Cancers, 2020, 12, 2293.	3.7	44
44	Protein Kinase C Î²II Plays an Essential Role in Dendritic Cell Differentiation and Autoregulates Its Own Expression. Journal of Biological Chemistry, 2005, 280, 28412-28423.	3.4	43
45	Targeting Aurora Kinases in Cancer Treatment. Current Drug Targets, 2011, 12, 2067-2078.	2.1	43
46	Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia. Investigational New Drugs, 2012, 30, 1107-1115.	2.6	43
47	Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. Blood Advances, 2020, 4, 1038-1050.	5.2	43
48	Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias. Blood, 2010, 116, 4591-4599.	1.4	41
49	A prospective randomised study of a rotary powered device (OnControl) for bone marrow aspiration and biopsy. Journal of Clinical Pathology, 2011, 64, 809-813.	2.0	41
50	Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors. Cancer Chemotherapy and Pharmacology, 2013, 71, 35-41.	2.3	41
51	A multicentre, phase <sc>II</sc> trial of ofatumumab monotherapy in relapsed/progressive diffuse large Bâ€cell lymphoma. British Journal of Haematology, 2013, 163, 334-342.	2.5	40
52	Complete Local and Abscopal Responses from a Combination of Radiation and Nivolumab in Refractory Hodgkin's Lymphoma. Radiation Research, 2018, 190, 322.	1.5	36
53	HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist. Leukemia, 2016, 30, 504-508.	7.2	34
54	Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors. ESMO Open, 2020, 5, e000866.	4.5	34

#	ARTICLE	IF	CITATIONS
55	Safety of CAR T-cell therapy in kidney transplant recipients. <i>Blood</i> , 2021, 137, 2558-2562.	1.4	33
56	PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma. <i>Modern Pathology</i> , 2020, 33, 324-333.	5.5	31
57	Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma. <i>Blood Cancer Discovery</i> , 2022, 3, 385-393.	5.0	29
58	Induction of CD8 T-cell-Ifn- $\gamma$ response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell lung carcinoma. <i>Cancer Gene Therapy</i> , 2003, 10, 850-858.	4.6	27
59	Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2018, 24, 6150-6159.	7.0	27
60	Human leukocyte antigen (HLA) DR15 is associated with reduced incidence of acute GVHD in HLA-matched allogeneic transplantation but does not impact chronic GVHD incidence. <i>Blood</i> , 2006, 107, 1970-1973.	1.4	26
61	Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , 2008, 41, 613-619.	2.4	25
62	T-cell lymphoma secondary to checkpoint inhibitor therapy. , 2020, 8, e000104.		25
63	Epstein-Barr-virus-positive large B-cell lymphoma associated with breast implants: an analysis of eight patients suggesting a possible pathogenetic relationship. <i>Modern Pathology</i> , 2021, 34, 2154-2167.	5.5	25
64	Leukapheresis reduces 4-week mortality in acute myeloid leukemia patients with hyperleukocytosis – a retrospective study from a tertiary center. <i>Leukemia and Lymphoma</i> , 2017, 58, 2110-2117.	1.3	24
65	Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy. <i>Blood Advances</i> , 2022, 6, 2867-2871.	5.2	24
66	Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism. <i>Leukemia and Lymphoma</i> , 2006, 47, 2339-2343.	1.3	23
67	Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial. <i>Leukemia and Lymphoma</i> , 2009, 50, 1096-1101.	1.3	22
68	Ibrutinib+rituximab followed by R-HCVAD as frontline treatment for young patients ( $\geq 65$ years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 406-415.	10.7	22
69	Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 665-671.	2.0	21
70	G6PD deficiency and severity of COVID19 pneumonia and acute respiratory distress syndrome: tip of the iceberg?. <i>Annals of Hematology</i> , 2021, 100, 667-673.	1.8	21
71	Targeting PIM kinase activity significantly augments the efficacy of cytarabine. <i>British Journal of Haematology</i> , 2012, 156, 129-132.	2.5	20
72	Mammalian target of rapamycin as a target in hematological malignancies. <i>Targeted Oncology</i> , 2011, 6, 53-61.	3.6	18

#	ARTICLE	IF	CITATIONS
73	The Transcription Factor Wilms Tumor 1 Confers Resistance in Myeloid Leukemia Cells against the Proapoptotic Therapeutic Agent TRAIL (Tumor Necrosis Factor $\alpha$ -related Apoptosis-inducing Ligand) by Regulating the Antiapoptotic Protein Bcl-xL. <i>Journal of Biological Chemistry</i> , 2012, 287, 32875-32880.	3.4	18
74	Utility of $^{18}$ F-fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma. <i>Annals of Oncology</i> , 2015, 26, 774-779.	1.2	17
75	Use of PEG-asparaginase in monomorphic epitheliotropic intestinal T-cell lymphoma, a disease with diagnostic and therapeutic challenges. <i>Ecancermedicalscience</i> , 2017, 11, 771.	1.1	17
76	Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses. <i>British Journal of Haematology</i> , 2021, 195, 201-209.	2.5	17
77	Safety Study of Salvage Chemotherapy High-Dose Ara-C/Mitoxantrone (HAM) and Type I FLT3-TKI Crenolanib in First Relapsed/Primary Refractory AML. <i>Blood</i> , 2016, 128, 3983-3983.	1.4	17
78	Long-term stability of a patient-convenient 1%mg/ml suspension of tacrolimus for accurate maintenance of stable therapeutic levels. <i>Bone Marrow Transplantation</i> , 2006, 37, 781-784.	2.4	15
79	Breast Implant-associated Anaplastic Large Cell Lymphoma. <i>Annals of Surgery</i> , 2022, 275, e245-e249.	4.2	15
80	Two cases of hepatic zygomycosis in allogeneic stem cell transplant recipients and review of literature. <i>Transplant Infectious Disease</i> , 2007, 9, 148-152.	1.7	13
81	Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2020, 26, 3546-3556.	7.0	13
82	Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Expressing Peripheral T-Cell Lymphomas. <i>Blood</i> , 2021, 138, 133-133.	1.4	13
83	Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma. <i>Blood Advances</i> , 2019, 3, 1356-1367.	5.2	12
84	A Comparison of Races and Leukemia Subtypes Among Patients in Different Cancer Survivorship Phases. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S114-S118.	0.4	11
85	Breast implant-associated anaplastic large cell lymphoma: clinical follow-up and analysis of sequential pathologic specimens of untreated patients shows persistent or progressive disease. <i>Modern Pathology</i> , 2021, 34, 2148-2153.	5.5	11
86	Lenalidomide Is Active in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Carrying Unfavorable Chromosomal Abnormalities.. <i>Blood</i> , 2007, 110, 754-754.	1.4	11
87	Dapsone-Induced Methemoglobinemia after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 241-242.	2.0	10
88	Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis. <i>Clinical Cancer Research</i> , 2019, 25, 6781-6787.	7.0	10
89	Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 1965-1973.	1.3	10
90	New paradigm for radiation in multiple myeloma: lower yet effective dose to avoid radiation toxicity. <i>Haematologica</i> , 2020, 105, e355-e357.	3.5	10

#	ARTICLE	IF	CITATIONS
91	Global Ophthalmology Practice Patterns during COVID-19 Pandemic and Lockdown. Ophthalmic Epidemiology, 2022, 29, 233-244.	1.7	10
92	Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer. Cancer Chemotherapy and Pharmacology, 2020, 85, 621-626.	2.3	9
93	CD8 expression in anaplastic large cell lymphoma correlates with noncommon morphologic variants and T-cell antigen expression suggesting biological differences with CD8-negative anaplastic large cell lymphoma. Human Pathology, 2020, 98, 1-9.	2.0	9
94	Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis. Haematologica, 2022, 107, 899-908.	3.5	9
95	Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma. ESMO Open, 2021, 6, 100172.	4.5	9
96	Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy. JAMA Network Open, 2020, 3, e2013935.	5.9	8
97	Gamma/Delta Phenotype in Primary Cutaneous T-cell Lymphomas and Lymphoid Proliferations. Surgical Pathology Clinics, 2021, 14, 177-194.	1.7	8
98	Ibrutinib Plus Rituximab and Venetoclax (IRV) Followed By Risk-Stratified Observation or Short Course R-Hypercvad/MTX in Young Patients with Previously Untreated Mantle Cell Lymphoma - Phase-II Window-2 Clinical Trial. Blood, 2021, 138, 3525-3525.	1.4	8
99	CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study. Blood, 2021, 138, 3560-3560.	1.4	8
100	Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma: Final Results from a Phase I/II Open Label Multi-Center Study. Blood, 2021, 138, 1365-1365.	1.4	8
101	Aggressive relapse of multiple myeloma with intracerebral extension and associated hemorrhage. Leukemia and Lymphoma, 2007, 48, 1228-1230.	1.3	7
102	Cryptococcal meningoencephalitis in patients with mantle cell lymphoma on ibrutinib. Ecancermedicallscience, 2018, 12, 836.	1.1	7
103	Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e51-e61.	0.4	7
104	Comparison of Access to Novel Drugs for Lymphoma and Chronic Lymphocytic Leukemia Between India and the United States. JCO Global Oncology, 2020, 6, 1124-1133.	1.8	7
105	MYC expression is associated with older age, common morphology, increased MYC copy number, and poorer prognosis in patients with ALK+ anaplastic large cell lymphoma. Human Pathology, 2021, 108, 22-31.	2.0	6
106	Ongoing, first-in-human, phase I dose escalation study of the investigational CD47-blocker TTI-622 in patients with advanced relapsed or refractory lymphoma.. Journal of Clinical Oncology, 2020, 38, 3030-3030.	1.6	6
107	High Frequency and Early Onset of Bone Mineral Density Loss Following Allogeneic Stem Cell Transplantation.. Blood, 2005, 106, 2011-2011.	1.4	6
108	Autologous stem cell transplantation for large B-cell lymphoma with secondary central nervous system involvement. Blood Advances, 2022, 6, 2267-2274.	5.2	6



#	ARTICLE	IF	CITATIONS
109	Cross Talk between Radiation and Immunotherapy: The Twain Shall Meet. Radiation Research, 2018, 189, 219-224.	1.5	5
110	Adoptive cell therapy for acute myeloid leukemia. Leukemia and Lymphoma, 2019, 60, 1370-1380.	1.3	5
111	Anaplastic Large Cell Lymphoma of the Breast Arising in a Burn Cicatrix. Aesthetic Surgery Journal, 2020, 40, NP159-NP163.	1.6	5
112	Angioimmunoblastic T-cell lymphoma associated with immune checkpoint inhibitor treatment. JAAD Case Reports, 2020, 6, 1264-1267.	0.8	5
113	Targeted based therapy in nodal T-cell lymphomas. Leukemia, 2021, 35, 956-967.	7.2	5
114	First Clinical Evidence of In Vivo Natural Killer (NK) Cell Modulation in Chronic Lymphocytic Leukemia (CLL) Patients (pts) Treated with Lenalidomide (L).. Blood, 2006, 108, 2109-2109.	1.4	5
115	Simultaneous presentation of acute monoblastic leukemia and mantle cell lymphoma: Case report and review of the literature. Leukemia and Lymphoma, 2005, 46, 1813-1818.	1.3	4
116	Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL. Leukemia and Lymphoma, 2020, 61, 1380-1387.	1.3	4
117	The impact of cell-of-origin, MYC/Bcl-2 dual expression and <i>MYC</i> rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy. Leukemia and Lymphoma, 2021, 62, 1361-1369.	1.3	4
118	Characterization of IMiDs (Immunomodulating Agents) Induced “Flare Reaction” in Patients with Chronic Lymphocytic Leukemia (CLL) and Correlation with Changes in Serum Cytokine Levels.. Blood, 2005, 106, 5049-5049.	1.4	4
119	Small cell/lymphohistiocytic morphology is associated with peripheral blood involvement, CD8 positivity and retained T-cell antigens, but not outcome in adults with ALK+ anaplastic large cell lymphoma. Modern Pathology, 2022, 35, 412-418.	5.5	4
120	Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide-based maintenance therapy. British Journal of Haematology, 2021, 193, e23-e26.	2.5	3
121	Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous Transplant. Clinical Cancer Research, 2021, 27, 5847-5856.	7.0	3
122	Phase 1 trial of carfilzomib in relapsed/refractory peripheral T-cell lymphoma. Annals of Hematology, 2022, 101, 335-340.	1.8	3
123	HLA-identical sibling stem-cell transplantation in first-remission AML. Blood, 2007, 110, 4619-4619.	1.4	2
124	Human leukocyte antigen DR4 is associated with inferior progression-free survival following allogeneic hematopoietic stem cell transplantation for lymphoid malignancies. Leukemia and Lymphoma, 2008, 49, 1494-1500.	1.3	2
125	Use of PEG-asparaginase in a case of Hepatosplenic T-cell lymphoma with long-term remission after stem cell transplantation. Ecancermedicallscience, 2018, 12, 872.	1.1	2
126	Triple-hit lymphoma of the cavernous sinus. Canadian Journal of Ophthalmology, 2019, 54, e61-e66.	0.7	2



#	ARTICLE	IF	CITATIONS
127	Acute myeloid leukemia with eosinophilia after cyclin-dependent kinases 4/6 inhibitor treatment due to underlying clonal hematopoiesis of indeterminate potential. American Journal of Hematology, 2019, 94, E82-E85.	4.1	2
128	SARS-CoV-2 in multiple myeloma: initial observation and management. Leukemia and Lymphoma, 2020, 61, 2763-2766.	1.3	2
129	Imaging Surveillance of Limited-stage Classic Hodgkin Lymphoma Patients After PET-CT-documented First Remission. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 533-541.	0.4	2
130	Anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma with MYC rearrangement. British Journal of Haematology, 2021, 192, e17-e21.	2.5	2
131	Final Results of Phase 1/1b Study of Tenalisib, Dual PI3K $\hat{\gamma}/\beta$ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma. Blood, 2019, 134, 2831-2831.	1.4	2
132	Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma Patients in Complete Metabolic Response at Time of Infusion. Blood, 2021, 138, 1740-1740.	1.4	2
133	The Echelon-2 Trial: 5-Year Exploratory Subgroup Analyses of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Vs CHOP in Frontline Treatment of Pts with CD30-Positive Peripheral T-Cell Lymphoma. Blood, 2021, 138, 135-135.	1.4	2
134	Acute lymphoblastic leukemia presenting with avascular necrosis of the elbow. Leukemia and Lymphoma, 2009, 50, 297-299.	1.3	1
135	BCL-W expression associates with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified. Blood Cancer Journal, 2021, 11, 153.	6.2	1
136	Aggressive primary cutaneous anaplastic large cell lymphoma with massive bilateral upper limb involvement at relapse. JAAD Case Reports, 2021, 17, 34-37.	0.8	1
137	Results From a Phase 1 Multicenter Trial of Alisertib (MLN8237)-An Investigational Aurora A Kinase Inhibitor-in Patients with Advanced Hematologic Malignancies. Blood, 2011, 118, 2477-2477.	1.4	1
138	Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China. Oncotarget, 2017, 8, 41620-41630.	1.8	1
139	Emerging Therapeutic Landscape of Peripheral T-Cell Lymphomas Based on Advances in Biology: Current Status and Future Directions. Cancers, 2021, 13, 5627.	3.7	1
140	The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Non-Hodgkin Lymphoma (NHL). Blood, 2020, 136, 17-18.	1.4	1
141	Gut Bacterial Diversity Associates with Efficacy of Anti-CD19 CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma. Blood, 2020, 136, 34-35.	1.4	1
142	Association of Vitamin D Deficiency with Inferior Treatment Outcomes in Patients with Newly Diagnosed Classic Hodgkin Lymphoma: MD Anderson Cancer Center Experience. Blood, 2020, 136, 27-28.	1.4	1
143	Sustained response to erythropoietin for anemia in NK-cell large granular lymphocytosis: a brief case report. Leukemia Research Reports, 2022, 17, 100292.	0.4	1
144	The Leukemic Phase of ALK-Negative Anaplastic Large Cell Lymphoma Is Associated with CD7 Positivity, Complex Karyotype, TP53 Deletion, and a Poor Prognosis. Cancers, 2021, 13, 6316.	3.7	1

#	ARTICLE	IF	CITATIONS
145	Unicentric Castleman disease, hyaline vascular variant, stromal rich, with increased plasma cells and a high level of serum IL-6: Raising the diagnostic and therapeutic issues. <i>Annals of Diagnostic Pathology</i> , 2019, 43, 151398.	1.3	0
146	Oral Abstract: TCL-150: The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S203.	0.4	0
147	Effect of Bone Marrow Hypoplasia Secondary to Reinduction Therapy for Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) on Outcomes after Blood and Marrow Transplantation (BMT).. <i>Blood</i> , 2006, 108, 3033-3033.	1.4	0
148	Osteonecrosis of the Jaw (ONJ) in Patients with Multiple Myeloma, Receiving Bisphosphonate Therapy, Is Independent of Renal Function: Single Institute Experience of an Emerging Clinical Problem.. <i>Blood</i> , 2006, 108, 5129-5129.	1.4	0
149	An Integer Weighted Genomic Mutation Scoring (IWGMS) Using the Trusight Myeloid Sequencing Panel (Illumina) Shows Higher Mortality in Patients with Intermediate Risk Acute Myeloid Leukemia- a Retrospective Study. <i>Blood</i> , 2016, 128, 2889-2889.	1.4	0
150	Demand and Supply of Face Masks during the COVID-19 Pandemic. <i>Smart and Sustainable Manufacturing Systems</i> , 2020, 4, 20200069.	0.7	0
151	No Difference in Survival Among Black Patients with Mycosis Fungoides and S��zary Syndrome: A Multicenter Retrospective Analysis. <i>Blood</i> , 2021, 138, 2441-2441.	1.4	0
152	Analysis of Factors Associated with Conversion to CR in Patients with Large B-Cell Lymphoma Achieving Day 30 PR after CAR T-Cell Therapy. <i>Blood</i> , 2021, 138, 3870-3870.	1.4	0
153	A Risk Score Incorporating Low Pass Whole Genome Sequencing of Cell Free DNA from Patients Receiving CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 38-38.	1.4	0
154	Factors Associated with the Improvement of Outcomes of High-Risk Relapsed Hodgkin Lymphoma (HL) Patients Receiving High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT): The MD Anderson Cancer Center Experience. <i>Blood</i> , 2020, 136, 17-18.	1.4	0
155	Nonmyeloablative Allogeneic Stem Cell Transplantation with or without Inotuzumab Ozogamicin for Lymphoid Malignancies. <i>Blood</i> , 2020, 136, 10-12.	1.4	0
156	Small cell/lymphohistiocytic morphology is associated with CD8 positivity, retained T cell markers, a trend of decreased PD-L1 expression, but not outcome in adults with ALK+ ALCL. , 2020, , .		0
157	A Novel Inflammatory Index Is Sufficient to Identify Hemophagocytic Lymphohistiocytosis in Adult Patients with Hematologic Malignancies. <i>Blood</i> , 2020, 136, 1-2.	1.4	0
158	Autologous Stem Cell Transplantation for Angioimmunoblastic T-Cell Lymphoma. <i>Blood</i> , 2020, 136, 40-41.	1.4	0
159	Herpesviruses Infections in CAR T Cell Recipients. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S381-S382.	1.2	0